Trials in New Mexico.
10 APOE4-relevant Alzheimer’s trials run in New Mexico — 2 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Non-carriers only, not for APOE4NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
- Drug trial for diagnosed APOE4 carriersNCT00575055Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Drug trial, genotype not specified, ARIA riskNCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…
- Observational study, not APOE4-specificNCT06284213Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
This is an observational study, not a drug test. Researchers will collect brain scans and blood samples from about 1,800 older adults, then follow them over…
- Drug trial, APOE4 handling not statedNCT06653153A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
This trial tests remternetug, an anti-amyloid antibody drug, against a placebo. It measures how long it takes for memory, thinking, or daily-function problems…
- Open to carriers, not 4-specificNCT06847321Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P.…
- Anti-amyloid drug — carriers verify eligibilityNCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This trial is testing trontinemab, an anti-amyloid antibody drug given by injection, against a placebo in people with early Alzheimer's — from mild cognitive…
- Gateway study, genotype not specifiedNCT07177352Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This is not a treatment trial. It is a pre-screening study run by Roche to figure out who might qualify for their future Alzheimer's disease trials.…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.